Form 4: Teva Pharma Exec Sells $6.2M in Shares After Option Exercise

Mark Sabag, Teva Pharmaceutical Industries' EVP, exercised stock options and subsequently sold over 216,000 ordinary shares for approximately $6.2 million.

Summary

• Mark Sabag, Executive Vice President, International Markets Commercial of Teva Pharmaceutical Industries Ltd. (TEVA), reported transactions on December 9, 2025.
• Sabag exercised stock options to acquire 118,724 Ordinary Shares at an exercise price of $18.61 per share.
• Following the exercise, Sabag held 269,720 Ordinary Shares directly.
• He then sold 118,724 Ordinary Shares at a weighted average price of $28.748 per share, with prices ranging from $28.705 to $28.845.
• Additionally, Sabag sold another 98,168 Ordinary Shares at a weighted average price of $28.7026 per share, with prices ranging from $28.675 to $28.745.
• After these transactions, Sabag beneficially owns 52,828 Ordinary Shares directly.
• The stock options were granted on February 9, 2018, and vested in three equal tranches on February 9, 2020, February 9, 2021, and February 9, 2022, with an expiration date of February 9, 2028.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the significant reduction in the executive's direct beneficial ownership, selling more shares than were acquired through the option exercise. While option exercise and sale is common, a substantial net reduction in holdings can sometimes be viewed with caution by investors, even if for personal reasons.

Positives

• The executive monetized vested equity, indicating a realization of value from previously granted compensation.
• The exercise price of $18.61 compared to the sale prices of approximately $28.70-$28.75 indicates a significant profit for the executive on the exercised options.

Negatives

• The executive sold a substantial number of shares (216,892 total) which included all shares acquired from the option exercise and an additional 98,168 shares from existing holdings, significantly reducing his direct beneficial ownership.
• Insider selling, especially a reduction in overall holdings, can sometimes be interpreted by the market as a lack of confidence in the company's near-term future prospects, although it is often for personal financial planning or diversification.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Management Comments

• Mark Sabag is identified as the Executive Vice President, International Markets Commercial.

Industry Context

Insider transactions, such as the exercise of stock options and subsequent sale of shares, are common occurrences in publicly traded companies across all industries. Executives often sell shares for personal financial planning, diversification, or to cover tax obligations associated with option exercises. The pharmaceutical industry, like others, sees such filings regularly as part of executive compensation and equity management.

Comparison to Industry Standards

• The exercise of vested stock options and subsequent sale of shares is a standard practice for executives to realize value from their equity compensation. This type of transaction is common across global benchmarks for executive compensation.
• The sale of shares to cover taxes and for personal liquidity is a widely accepted reason for insider selling and is not inherently indicative of a negative outlook on the company's future.
• Compared to other large pharmaceutical companies, executive compensation often includes significant equity components, leading to similar Form 4 filings when options vest and are exercised.

Stakeholder Impact

• Shareholders: May interpret the significant insider selling as a signal, potentially influencing their perception of management's confidence in the company's future. The reduction in direct holdings could be seen as a negative, though it's a common practice for personal financial management.
• Employees: No direct impact mentioned, but general market sentiment can indirectly affect employee morale or perception of company stability.

Key Dates

Recommendation

While the executive realized a significant profit from exercising options, the substantial sale of shares, including a net reduction in overall direct holdings, warrants a 'hold' recommendation. This single insider transaction, while notable in size, does not provide sufficient information to fundamentally alter the investment thesis for Teva Pharmaceutical Industries. Investors should monitor broader company performance, industry trends, and other insider activity rather than reacting solely to this filing, as such sales are often for personal financial planning.

Keywords

Teva Pharmaceutical Industries, TEVA, Insider Trading, Form 4, Stock Options, Executive Compensation, Share Sale, Mark Sabag, Pharmaceuticals